Non metastatic cell protein 1 expression and clinical significance in prostate cancer

Abstract

Objective To explore the role of non metastatic cell protein 1 (NME1) in diagnosing prostate cancer (PCa) and judging early metastasis of PCa.Methods The gene chip was used to screen NME1 in PCa and benign prostatic hyperplasia (BPH) tissues,the differential expression of NME1 prostein in PCa and adjacent tissues was analyzed by using fluorescence 2-D difference gel electrophoresis (2DDIGE) technology,and validated by using immunohistochemistry (IHC).The NME1 IHC score and clinicopathological parameters of PCa patients were analyzed.Results Relative to BPH tissues the expression of NME1 was down-regulated in PCa tissues by gene chip screening (P ＜ 0.01),and relative to adjacent tissues the same phenomenon was observed in PCa tissues by using 3D-DIGE technology (P ＜0.01).The expression of NME1 was negatively correlated with serum PSA levels (P ＜ 0.05),Gleason score (P ＜0.01) and TNM stage (P ＜ 0.05),positively correlated with metastasis (P ＜ 0.01),but not correlated with age (P ＞ 0.05).NME1-positive PCa patients had a lower overall survival rate (Log Rank =11.117,P ＜0.01),but there was no significant difference in biochemical recurrence rate between NMEl-negative and NMEl-positive PCa patients (Log Rank =0.247,P ＞ 0.05).Conclusion The low expression of NME1 is closely related with the malignancy of PCa,and the loss of NME1 may promote tumor cell growth.Serum PSA levels in combination with NME1 levels can be used to diagnose PCa early and judge the degree of the malignancy of PCa.The high expression of NME1 may promote PCa metastasis. Key words: Non metastatic cell protein 1 gene; Prostate carcinoma; Diagnosis